LKT Labs

Biochemicals for Life Science Research

Tolfenamic Acid

Tolfenamic Acid

Product ID T5846
Cas No. 13710-19-5
Purity ≥98%
Product Unit SizeCostQuantityStock
5 g $71.50 In stock
25 g $245.30 In stock
50 g $377.90 In stock
Bulk Quote

Quicklinks

Description

Tolfenamic acid is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and anticancer chemotherapeutic activities; it inhibits COX-1 and COX-2. Tolfenamic acid inhibits leukotriene B4 (LTB4) production, degranulation, and migration in polymorphonuclear leukocytes. Tolfenamic acid also downregulates expression of cyclin D1, increases ER stress, and induces apoptosis in colorectal cancer cells, inhibiting tumor growth in vivo. Additionally, tolfenamic acid also decreases expression of VEGF, VEGFR1, HGFR/c-MET, survivin, Bcl-2, and Sp proteins in cellular models of colorectal cancer.

Product Info

Cas No.

13710-19-5
Purity

≥98%
Formula

C14H12ClNO2
Formula Wt.

261.70
Chemical Name

2-[(3-Chloro-2-methylphenyl)amino]benzoic acid
IUPAC Name

2-(3-chloro-2-methylanilino)benzoic acid
Synonym

Clotam, Tolfedine, Tolfine
Melting Point

207-207.5°C
Solubility

Slightly soluble in water; freely sol in buffers with pH >8.2
Appearance

Off White Crystal Powder, Odorless

Shipping and Storage

Store Temp

Ambient
Ship Temp

Ambient

Downloads

MSDS

T5846 MSDS PDF
Info Sheet

T5846 Info Sheet PDF

References

Pathi S, Li X, Safe S. Tolfenamic acid inhibits colon cancer cell and tumor growth and induces degradation of specificity protein (Sp) transcription factors. Mol Carcinog. 2014 Feb;53 Suppl 1:E53-61. PMID: 23670891.

Zhang X, Lee SH, Min KW, et al. The involvement of endoplasmic reticulum stress in the suppression of colorectal tumorigenesis by tolfenamic acid. Cancer Prev Res (Phila). 2013 Dec;6(12):1337-47. PMID: 24104354.

Kankaanranta H, Moilanen E, Vapaatalo H. Comparison of in vitro effects of flunixin and tolfenamic acid on human leukocyte and platelet functions. Inflammation. 1993 Aug;17(4):417-25. PMID: 8406686.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • M4452

    MLN2480

    Raf inhibitor.

    ≥98%
  • S8253

    Sunitinib Malate

    Indoline; PDGFR, VEGFR, c-KIT, FLT3, mTORC1 inh...

    ≥98%
  • M577521

    Monascorubrin

    Bulgarialactone azaphilone

    ≥98%
  • R0351

    Ramoplanin

    Peptide; peptidoglycan inhibitor.

    ≥90%
  • B3200

    BI-2536

    PLK1 inhibitor.

    ≥98%
  • K040009

    KB-0742 dihydrochloride

    CDK9 inhibitor.

    ≥99%
  • P0344

    Palbociclib Isethionate

    CDK4/6 inhibitor.

    ≥98%
  • L9701

    LY-450139

    GHS-R1a agonist, γ-secretase inhibitor.

    ≥98%
  • G1646

    Geldanamycin

    HSP90 inhibitor.

    ≥97%
  • S760004

    Stachybotrylactam

    Spirodihydrobenzofuranlactam

    ≥98%
  • A9818

    Azelastine Hydrochloride

    TRPV1 agonist, histamine H1 antagonist.

    ≥98%
  • A0833

    Acipimox

    Niacin derivative.

    ≥98%
  • P3441

    PIK-294

    p110δ PI3K inhibitor.

    ≥98%
  • C211324

    CFI-400945

    PLK4 inhibitor.

    ≥98%
  • A5478

    Antipain Dihydrochloride

    Oligopeptide found in Actinomycetes; protease i...
  • D5690

    Doxazosin Mesylate

    Quinazoline; α1-adrenergic antagonist.

    ≥98%
  • B0108

    Bactenecin

    Cathelicidin derivative, antimicrobial peptide,...

    ≥95%
  • C1660

    CEP-32496

    V600E B-Raf inhibitor.

    ≥98%
  • E325125

    EIDD-2801

    COVID-19 research

    ≥98%
  • N0062

    D,L-Naproxen

    NSAID; COX-1/2 inhibitor.

    ≥98%